Sanofi Navigates Patent Cliff, Expects Growth To Return In Second Half 2013
This article was originally published in The Pink Sheet Daily
Sanofi says the worst of its patent cliff is past, and with 15 new assets nearing the market in the next three years and an industry-leading business in emerging markets, the French group is well positioned for growth.
You may also be interested in...
GlaxoSmithKline will implement a new £1.5 billion restructuring program to improve commercial efficiencies in Europe and adopt new manufacturing processes, following sales and profits shortfalls in 2012.
Novartis says long-time chairman Daniel Vasella has decided to leave the Swiss drug maker and its board has chosen former COO and current Bayer healthcare division head Jorg Reinhardt to replace him.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.